Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
BRIEF-PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002 July 21 (Reuters) - Jupiter Neurosciences Inc JUNS.O:
PHARMALA BIOTECH EXECUTES DEFINITIVE LICENSE AGREEMENT GRANTING JUPITER NEUROSCIENCES EXCLUSIVE U.S. RIGHTS TO ALA-002
PHARMALA BIOTECH - DEAL VALUED UP TO $100 MILLION INCLUDING $3.33 MILLION UPFRONT AND MILESTONES PLUS ROYALTIES
PHARMALA BIOTECH - UPFRONT PAYMENT OF $3.33 MILLION: $1.50 MILLION CASH, $1.83 MILLION IN JUPITER STOCK
PHARMALA BIOTECH - DEVELOPMENT AND REGULATORY MILESTONES UP TO $23.33 MILLION INCLUDING $20 MILLION FOR FDA APPROVAL
PHARMALA BIOTECH - COMMERCIALIZATION MILESTONES UP TO $73.33 MILLION BASED ON U.S. NET SALES TARGETS
PHARMALA BIOTECH - TO RECEIVE 3% ROYALTY ON U.S. NET SALES AFTER THIRD MILESTONE
PHARMALA BIOTECH - TO MANUFACTURE GMP-GRADE ALA-002 FOR JUPITER UNDER SEPARATE SUPPLY AGREEMENT
Source text: ID:nGNXb746NG
Further company coverage: JUNS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmala Biotech Holdings
See all newsBrief: Pharmala Biotech Holdings Rua Bioscience And Pharmala Biotech Partner To Supply Medicinal Mdma In New Zealand
Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
Brief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
Brief: Pharmala Executes Binding Letter Of Intent For Formation Of Special Purpose Vehicle To Develop Patented Novel Mdxx Molecule Apa-01
Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders